

**Room 501 A-C, Los Angeles Convention Center
Epidemiology 11**
Inflammation, Immunity, and Novel Pathways

Chairpersons: Christine F. Skibola and James R. Cerhan

10:00 Introduction.

- 10:10 4116 Risk of breast cancer and polymorphisms within the NF- κ B pathway.** Ellen L. Goode, Janet E. Olson, Zachary S. Fredericksen, Robert A. Vierkant, Linda E. Kelemen, David N. Rider, Wen Liu-Mares, Csilla Szabo, Xianshu Wang, V. Shane Pankratz, Celine M. Vachon, James R. Cerhan, Fergus J. Couch.
- 10:25 4117 Systematic evaluation of the inflammation pathway identifies interleukin 1 gene variants associated with lung cancer risk.** Eric A. Engels, Xifeng Wu, Jian Gu, Qiong Dong, Jun Liu, Margaret R. Spitz.
- 10:40 4118 Genetic variation in transforming growth factor beta 1, serum levels and risk of colorectal neoplasia.** Barbara S. Saltzman, Robert Decker, Andre G. Theriault, Lance Yokochi, Geoffrey K. Maiyoh, Jennifer Yamamoto, Loic Le Marchand.
- 10:55 4119 Variants in inflammation-related genes and risk of prostate cancer: the PLCO study.** Kim N. Danforth, Richard B. Hayes, Lori C. Sakoda, Wen-Yi Huang, Nilanjan Chatterjee, Jinbo Chen, Lisa W. Chu, Meredith Yeager, Elizabeth A. Platz, Dominique S. Michaud, Stephen J. Chanock, Ann W. Hsing.
- 11:10 4120 Genetic variation in CD83 increases susceptibility to cervical cancer and the protein co-localizes to the Golgi apparatus and cell surface in cervical cancer cell lines.** Zhengyan Zhang, Ingrid Borecki, Loan Nguyen, Duanduan Ma, Kimberly Smith, Phyllis Huettner, David Mutch, Thomas Herzog, Randall Gibb, Matthew Powell, Stewart Massad, Enrique Hernandez, Patricia Judson, Elizabeth Swisher, Pery Grigsby, Jianduan Li, Daniela Gerhard, Janet Rader.
- 11:25 4121 Toll-like receptor gene polymorphisms and the risk of lymphoma.** Alexandra Nieters, Silvia De Sanjosé, Yolanda Benavante, Nikolaus Becker, Gigi Cocco, Marc Maynadié, Anthony Staines, Lenka Foretova, Martine Vornanen, Paolo Boffetta, Paul Brennan.
- 11:40 4122 International Lung Cancer Consortium: Pooled analysis of sequence variants in DNA repair pathway.** Rayjean J. Hung, David C. Christiani, Aage Haugen, Angela Risch, Odilia Popanda, Simone Benhamou, Qing Lan, Margaret Spitz, Paolo Vineis, Curtis Harris, H. Erich Wichmann, Loic Le Marchand, Chikako Kiyohara, Zuo-Feng Zhang, Adeline Seow, Paolo Boffetta, Paul Brennan, The International Lung Cancer Consortium Investigators.
- 11:55 4123 DNA repair capacity (DRC) as a predictor of lung cancer risk in never smokers and their relatives.** Olga Gorlova, Shih-Feng Weng, Yiqun Zhang, Christopher Amos, Margaret Spitz, Qingyi Wei.
- 12:10 4124 Iron intake, genetic polymorphisms of myeloperoxidase and superoxide dismutase 2, and prostate cancer risk in CARET cohort.** Ji-Yeob Choi, Marian L. Neuhouser, Matt Barnett, Chi-Chen Hong, Alan R. Kristal, Mark Thornquist, Irena B. King, Gary Goodman, Christine B. Ambrosone.
- 12:25 4125 Polyphenol-rich food and beverage intake, endogenous estrogens, UGT1A1 polymorphisms and endometrial cancer risk.** Sandra L. Deming, Wei Zheng, Wang-Hong Xu, Qiuyin Cai, Yong-Bing Xiang, Xiao-Ou Shu.
- 12:40 4126 Genetic variation in the one carbon transfer pathway and ovarian cancer risk.** Linda E. Kelemen, Robert A. Vierkant, Zachary S. Fredericksen, Madhura K. Gadre, V. Shane Pankratz, Julie M. Cunningham, Janet E. Olson, Mark Liebrow, Ed Iversen, Cathy M. Phelan, Yifan Huang, Joellen M. Schildkraut, Thomas A. Sellers, Ellen L. Goode.
- 12:55 4127 Association of SNPs in glycosylation genes with risk of epithelial ovarian cancer.** Thomas A. Sellers, Yifan Huang, Catherine Phelan, Zachary S. Fredericksen, Shane Pankratz, Ellen L. Goode, Robert A. Vierkant, Mark Liebrow, Linda Kelemen, Julie M. Cunningham, Joellen Schildkraut.

1:10 Discussion.
**Room 409 A-B, Los Angeles Convention Center
Clinical Research 16**
Clinical Immunology and Biological Therapy

Chairpersons: Michael B. Atkins and Kim A. Margolin

10:00 Introduction.

- 10:10 4128 A20 is an antigen presentation attenuator and its inhibition hyperactivates antitumor immunity.** Xiaotong Song, Kevin Evel-Kabler, Lei Shen, Xue Huang, Siyi Chen.
- 10:25 4129 Clinical importance and therapeutic potential of targeting PD-L/PD-1 pathway in pancreatic cancer.** Takeo Nomi, Masayuki Sho, Takahiro Akahori, Kaoru Hamada, Hiromichi Kanehiro, Hideo Yagita, Miyuki Azuma, Yoshiyuki Nakajima.
- 10:40 4130 Natural immunity to MUC1 tumor antigen in mice with premalignant (endometriosis) or malignant (ovarian carcinoma) lesions.** Rachel R. Chrissluis, Olivera J. Finn, Anda M. Vlad.
- 10:55 4131 Identification of an immunological signature of tumor rejection in the neu transgenic mouse.** Hailing Lu, Amy Chang, Emily Larson, Ekram Gad, Mary L. Disis.
- 11:10 4132 Hormone and radiation therapy induce antigen-specific immune responses in the Shionogi mouse tumor model and human prostate cancer patients.** Nancy J. Nesslinger, Sara Hahn, Rob Sahota, Charles Ludgate, Mary Bowden, Paul Blood, Wayne Beckham, Paul Rennie, Howard H. Pai, Brad H. Nelson.
- 11:25 4133 Alemtuzumab activity and CD52 expression in human CD52 transgenic mice.** Yanping Hu, Jacqueline Shields, Sam Rao, Michael Lamorte, Lisa Woodworth, Bill Kennedy, Elizabeth Hutto, Bruce Roberts, William M. Siders, Johanne Kaplan.
- 11:40 4134 Expression of the PAM4-reactive, MUC1 epitope, in pancreatic intraepithelial neoplasia and adenocarcinoma.** David V. Gold, Zarir Karanjawala, David E. Modrak, David M. Goldenberg, Ralph H. Hruban.
- 11:55 4135 The canine spontaneous glioblastoma as preclinical large animal model for brain cancer gene therapy.** Marianela Candolfi, James F. Curtin, W. S. Nichols, Akm G. Muhammad, Mariana Puntel, Gwendalyn D. King, Weidong Xiong, Kurt M. Kroeger, Carlos Barcia, Chunyan Liu, Sonali Mondkar, G. E. Pluhart, Elizabeth A. Mc Niel, John R. Ohlfest, Andrew B. Freese, Peter F. Moore, Donna Palmer, Philip Ng, John Young, Pedro R. Lowenstein, Maria G. Castro.
- 12:10 4136 CD52 over-expression affects rituximab-associated complement mediated cytotoxicity (CMC) but not antibody-dependent cellular cytotoxicity (ADCC): Pre-clinical evidence targeting CD52 with alemtuzumab to reverse acquired resistance to rituximab in Non-Hodgkin's Lymphoma (NHL).** Raymond I. Cruz, Francisco J. Hernandez-Ilizaliturri, Joy M. Knight, Myron S. Czuczman.
- 12:25 4137 New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells.** Xing Du, Mitchell Ho, Ira Pastan.
- 12:40 4138 Complement activation and resistance within the cerebrospinal fluid following intraventricular administration of anti-CD20 in the treatment of central nervous system lymphoma.** Cigall Kadoch, Jon Karch, Hannah Lee, Marc A. Shuman, James Rubenstein.
- 12:55 4139 Identification of antibody responses induced in patients with metastatic hormone-refractory prostate cancer (HRPC) treated with a GM-CSF-transduced allogeneic prostate cancer immunotherapy.** Thomas C. Harding, Minh C. Nguyen, Kathryn Koprivnikar, Guang Huan-Tu, Karin U. Jooss.

1:10 Discussion.

**Room 304 A-C, Los Angeles Convention Center
Cellular and Molecular Biology 49
Cancer Epigenetics**

Chairpersons: Charles W.M. Roberts and Toshikazu Ushijima

10:00 Introduction.

10:10 4140 Large-scale identification of long-range epigenetic alterations in breast cancer. Céline Vallot, Nicolas Stransky, Fabien Reyat, Isabelle Bernard-Pierrot, Anne Vincent-Salomon, Gaëlle Pierron, Paul Elvin, Andrew Cassidy, Alexander Graham, Carolyn Spraggon, Jean-Paul Thiery, Brigitte Sigal-Zafrani, Xavier Sastre-Garau, Olivier Delattre, François Radvanyi.

10:25 4141 A truncated DNMT3B protein expressed in cancer cells disrupts murine embryonic development. Lucy A. Godley, Chris Hendrick, Gopal Patel, Mrinal Shah, Adam Mikolajczyk, Sonja E. Volker, Kelly R. Ostler.

10:40 4142 Novel DNA hypomethylating agents: non-nucleoside compounds that do not incorporate into DNA selectively induce degradation of DNA methyltransferase I (DNMT1) in human cancer cells by the proteasomal pathway and re-express silenced tumor suppressor genes. Jharna Datta, Kalpana Ghoshal, Huban Kutay, Pasit Phiasivongsa, Sanjeev Redkar, Samson T. Jacob.

10:55 4143 Tumor suppressor p16INK4a regulates polycomb-mediated DNA hypermethylation in human mammary epithelial cells. Paul A. Reynolds, Mahvash Sigaroudinia, Giuseppe Zardo, Matthew Wilson, Geoffrey Benton, Joseph F. Costello, Thea D. Tlsty.

11:10 4144 Role of nucleosomal occupancy in the epigenetic silencing of the MLH1 CpG island. Joy C. Lin, Shinwu Jeong, Gangning Liang, Daiya Takai, Merhaz Fatemi, Einav Nili gal-Yam, Yvonne C. Tsai, Peter A. Jones.

11:25 4145 The aberrant epigenetic profile of the HOXA gene cluster in human breast cancer. Taylor J. Jensen, Petr Novak, Marc M. Oshiro, Ryan J. Wozniak, George S. Watts, Walter T. Klimecki, Christina Kim, Bernard W. Futscher.

11:40 4146 Transcriptional silencing of tumor suppressor gene *p15* by its antisense RNA. Wenqiang Yu, Mei Gao, Patrick Ongango, Judith Karp, Andrew P. Feinberg, Hengmi Cui.

11:55 4147 The impact of HDAC2 mutations in the gene expression profile of human tumors. Santiago Roperro, Esteban Ballestar, Mario F. Fraga, Miguel Alaminos, Richard Hamelin, Hiroyuki Yamamoto, Diego Arango, Torben F. Orntoft, Lauri A. Aaltonen, Simó Schwartz, Jr., Manel Esteller.

12:10 4148 Genome-wide profiling of DNA methylation reveals a cluster of densely methylated CpG island promoters in normal tissues. Lanlan Shen, Yutaka Kondo, Yi Guo, Xinli Chen, Saira Ahmed, Jean-Pierre J. Issa.

12:25 4149 Comparison of three microarray-based technologies for genome-wide identification of DNA methylation patterns. Hui Liu, Heather Holster, Saurabh Agarwal, Mayumi Oda, Tibor Rauch, Gerd Pfeifer, John Grealley, Bing Ren, Xinmin Zhang.

12:40 4150 Normal large-scale variation in genomic DNA methylation patterns. Jonathan J. Davies, Ian M. Wilson, Bradley P. Coe, Raj Chari, Calum Macaulay, Carolyn J. Brown, Wan L. Lam.

12:55 4151 Gender- and tissue-specific response to zebularine in *Apc^{min/+}* mice. Christine B. Yoo, Jody Chuang, Hyangmin Byun, Allen S. Yang, Peter W. Laird, Victor E. Marquez, Peter A. Jones.

1:10 Discussion.

**Room 511 A-C, Los Angeles Convention Center
Cellular and Molecular Biology 50
Non-Receptor Mediated Signaling**

Chairpersons: Peter K. Vogt and David Schlaepfer

10:00 Introduction.

10:10 4152 Steroid hormone receptor coactivator, E6-associated protein (E6-AP) regulates PI3K-Akt signaling and prostate cell growth. Sathish Srinivasan, Guilian Fu, Sarath Dhananjayan, Shazia Zafar, Zafar Nawaz.

10:25 4153 RACK1 is an essential scaffolding protein for regulation of FAK phosphorylation by IGF-I and integrins, and for tumor cell proliferation. Patrick A. Kiely, George S. Baillie, Miles D. Houslay, Rosemary O'Connor.

10:40 4154 Regulation of protein phosphatase 2A (PP2A) B subunits by Bcr/Abl: Potential targets for chronic myeloid leukemia. Kathryn G. Roberts, Leonie K. Ashman, Alistair T. Sim, Nicole M. Verrills.

10:55 4155 Activation of mTOR by inhibitors of translation is dependent on PKC-delta. Jun Zhan and Peter J. Houghton.

11:10 4156 Identification of a novel regulator for smoothened signaling in human cancers. Jingwu Xie, Tao Sheng, Xiaoli Zhang.

11:25 4157 Interaction of tumor suppressor FUS1 with nuclear receptor tyrosine kinase RAR- α proteins enhances the sensitivity of non-small cell lung cancer (NSCLC) to retinoid-mediated therapy. Arifumi Iwamaru, Wuguo Deng, Hiroyuki Kawashima, Jack A. Roth, Lin Ji.

11:40 4158 CARMA3 deficiency abrogates G-protein-coupled receptor induced NF- κ B activation. Brian C. Grabiner, Marzenna Blonska, Pei-Chun Lin, Yun You, Donghai Wang, Jiyuan Sun, Chen Dong, Xin Lin.

11:55 4159 TCEAL 7: A putative novel tumor suppressor modulates NF κ B activity. Ramandeep Rattan, Jeremy Chien, Keishi Narita, Julie Staub, Shailendra Giri, Viji Shridhar.

12:10 4160 Identification of 14-3-3 as a substrate for K63-linked polyubiquitination after DNA damage using a proteomic based linkage-specific ubiquitin trap. Roland K. Chiu, Christelle Vreuls, Lin Weng, François Guillonnet, Jean-Marie Frère, Edwin De Pauw, Philippe Lambin, Bradley Wouters.

12:25 4161 Leptin-induced growth stimulation of breast cancer cells involves recruitment of histone acetyltransferases and mediator complex to cyclin D1 promoter via activation of Stat3. Dipali Sharma and Neeraj Saxena.

12:40 4161A Detection of endogenous protein interactions *in situ*. Ola Soederberg.

12:55 Discussion.

Room 404 A-B, Los Angeles Convention Center
Tumor Biology 28
Angiogenesis and Lymphangiogenesis in Tumor Metastasis

Chairpersons: Kari K. Alitalo and Judith A. Varner

- 10:00 Introduction.**
- 10:10 Growth factors prepare the lymphovascular system for metastasis.** Kari K. Alitalo, University of Helsinki, Helsinki, Finland.
- 10:40 Dissecting steps of lymphatic metastasis.** Rakesh K. Jain, Massachusetts General Hospital, Boston, MA.
- 11:10 4162 Preparing the "soil": The primary tumor induces vasculature reorganization in the sentinel lymph node prior to the arrival of metastatic cancer cells.** Chao-Nan Qian, Bree Berghuis, Galia Tsarfaty, Marybeth Bruch, Eric J. Kort, Jon Ditlev, Ilan Tsarfaty, Eric Hudson, David G. Jackson, David Petillo, Jindong Chen, James H. Resau, Bin Tean Teh.
- 11:25 4163 VEGF overexpression increases stromal content in both primary tumor and metastatic lesions.** Anshu Mittal Roy, Jaideep Thottassery, Yulia Maxuitenko, Rongbao Li, Francis G. Kern, Zhican Qu.
- 11:40 4164 Nitric oxide mediates lymphangiogenesis and lymphatic metastasis.** Jeroen Hagendoorn, Johanna Lahdenranta, Timothy P. Padera, Gregory M. Nelson, Tohru Hoshida, Satoshi Kashiwagi, Rakesh K. Jain, Dai Fukumura.
- 11:55 4165 The role of inflammatory neutrophils and neutrophil-derived MMP-9 in physiologic and tumor angiogenesis.** Veronica Ardi, Mark Madsen, Elena Deryugina, James Quigley.
- 12:10 4166 TGF- β 1 signaling enhances tumor angiogenesis and metastasis.** Andrei V. Bakin, Alfiya Safina, Richard Mazurchuck, Joseph Sperry.
- 12:25 4167 Expression and function of Robo4.** Alexander Legg, Helen Sheldon, Maud Andre, Jan Kitajewski, Roy Bicknell.
- 12:40 4168 Role of small GTPase RhoB in breast tumorigenesis.** Shiva Kazerounian, Durga Udayakumar, Damien Gerald, George C. Prendergast, Laura E. Benjamin.
- 12:55 4169 p14ARF inhibits tumor-induced angiogenesis by a p53-independent sp1/TIMP3 mechanism.** Abdessamad Zerrouqi, Beata Pyrzynska, Maria Febbraio, Daniel J. Brat, Erwin G. Van Meir.
- 1:10 Discussion.**

Room 406 A-B, Los Angeles Convention Center
Chemistry 8
Drug Discovery and Design 2: Targeted Design and Delivery

Chairpersons: Diane H Boschelli and Chengguo Xing

- 10:00 Introduction.**
- 10:10 4170 Structure activity relationships for 5-substituted pyrrolo[2,1-f][1,2,4]triazine-based inhibitors of pan-HER/VEGFR2 kinases: Identification of the clinical candidate.** Ashvinikumar V. Gavai, Ping Chen, Derek Norris, Brian E. Fink, Harold Mastalerz, Yufen Zhao, Wen-Ching Han, Guifen Zhang, Walter Johnson, Edward Ruediger, Pierre Dextraze, Soong-Hoon Kim, Kenneth Leavitt, Kyoung Kim, Songfeng Lu, Peter Zheng, Arvind Mathur, Dinesh Vyas, John S. Tokarski, Chiang Yu, Simone Oppenheimer, Hongjian Zhang, Francis Lee, Tai W. Wong, Gregory D. Vite.
- 10:25 4171 Identification of GSK461364, a novel small molecule polo-like kinase 1 inhibitor for the treatment of cancer.** Kevin W. Kuntz, James M. Salovich, Robert A. Mook, Jr., Kyle A. Emmitte, Stanley D. Chamberlain, Tara R. Rheault, Keith R. Hornberger, Holly K. Emerson, Stephen C. Smith, Brian J. Wilson, Ronda G. Davis-Ward, Kelly H. Donaldson, George M. Adjabeng, Kristen E. Nailor, Daniel F. Hassler, Gary K. Smith, Timothy J. Lansing, Derek Duckett, Victoria Knick, Randy T. McConnell, Jeffrey R. Jackson, Mui Cheung.
- 10:40 4172 Design, synthesis, SAR and biological evaluation of selective Tie-2 inhibitors.** Nandini Patel, Joel Arcari, Deborah Baker, Gary Borzillo, Jinshan Chen, Tracey Clark, Bruce Cohen, William Hungerford, Shefali Kakar, Elisabeth Knauth, Luis Martinez-Alsina, Matthew Marx, Susan Lagreca, Catherine Soderstrom, George Tkalecic, Merin Troutman, Patrick Vincent, Matthew Wessel, Yong Lu, Carl Thompson, Aaron Kanter.
- 10:55 4173 Aurora kinase inhibitors: Lead structure identification from the Tetrahydrobenzo[b]thiophene class.** Peter Sennhenn, Tilmann Brandstetter, Alexander Backes, Roland Koestler, Joachim Vogt, Lars Neumann, Matthias Baumann, Gabriele Zylbarth, Gerhard Mueller.
- 11:10 4174 From tuberculosis to cancer: a chemical proteomics approach.** Marc-Nicola Sommer, Klaus Godl, Lars Neumann, Gerhard Mueller, Bert Klebl, Doris O. Hafenbradl.
- 11:25 4175 The combi-targeting concept: a new cell signaling-based model for the selective targeting of the epidermal growth factor receptor (EGFR)- and Her2-expressing solid tumor cells by the complex combi-molecule RB24 (NSC 741279).** Ranjita Banerjee, James P. McNamee, Bertrand J. Jean-Claude.
- 11:40 4176 Development of unique estrogen-cytotoxic hybrid molecules showing affinity for the estrogen receptor and *in vivo* anticancer activity.** Caroline Descôteaux, Josée Provencher-Mandeville, Céline Van Themsche, Valérie Leblanc, Geoffroy Bélanger, Sophie Parent, Atul Gupta, Eric Asselin, Gervais Bérubé.
- 11:55 4177 Chemoproteomics-driven drug discovery: identification of novel hsp90 inhibitors.** Steven E. Hall, Amy Barabasz, Tom Barta, Laura Dubois, Jeron Eaves, Patrick Fadden, Briana Foley, Tiffany Freed, Gunnar Hanson, Lindsay Hinkley, Mei Hu, Matthew Jenks, Meredith Lewis, Wei Ma, Jeffrey Partridge, Bert Pronk, John Rice, Anisa Scott, Melanie Silinski, Jon-Paul Strachan, Paul Steed, James Veal, Katleen Verleysen, Timothy Haystead.
- 12:10 4178 A novel trans-lymphatic drug delivery system effectively controls lymphatic metastasis in orthotopic colon cancer model.** Jiang Liu, Ho-Lun Wong, Xiao Y. Wu, Ming S. Tsao, Michael R. Johnston.
- 12:25 4179 Assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using phi29 motor pRNA.** Songchuan Guo, Annette Khaled, Feng Li, Peixuan Guo.
- 12:40 4180 Nanoconjugate with different monoclonal antibodies to inhibit molecular targets important for tumor angiogenesis.** Julia Y. Ljubimova, Manabu Fujita, Natalya M. Khazenzon, Bong-Seop Lee, Eggehard Holler, Keith L. Black.
- 12:55 4181 Her2 targeted nanoparticle bioconjugates for breast cancer treatment.** Frank Alexis, Pamela Basto, Etgar Levy-Nissenbaum, Frank Gu, Aleksandar Radovic-Moreno, Robert Langer, Omid Farokhzad.
- 1:10 Discussion.**

**Room 515 A, Los Angeles Convention Center
Experimental and Molecular Therapeutics 36
Genetic and Antibody Based Experimental Therapies**

Chairpersons: F. Stephen Hodi and Robert S. Carter

- 10:00 Introduction.**
- 10:10 4182 Eradication of resistant prostate cancer by a novel gene therapy approach.** Devanand Sarkar, Irina Lebedeva, Zao-Zhong Su, Eun Sook Park, Nicollaq Vozhilla, Paul B. Fisher.
- 10:25 4183 Modulation of tumor microenvironment enhances oncolytic virus therapy.** Kazuhiko Kurozumi, Jayson Hardcastle, Ming Yang, Gregory Christoforidis, William Carson, E. Antonio Chioocca, Balveen Kaur.
- 10:40 4184 VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth.** Chae-Ok Yun, Ji Young Yoo, Joo-Hang Kim, Joohyuk Sohn, Hyejin Choi.
- 10:55 4185 Targeted release of oncolytic measles virus by blood outgrowth endothelial cells *in situ* inhibits orthotopic gliomas.** Jiwu Wei, Joachim Wahl, Takafumi Nakamura, Detlef Stiller, Klaus-Michael Debatin, Christian Beltinger.
- 11:10 4186 GA101: A humanized third generation type II CD20 antibody with superior cell death induction and glycoengineered Fc region for enhanced ADCC.** Pablo Umana, Ekkehard Moessner, Peter Bruenker, Gabriele Unsin, Ursula Puentener, Roger Grau, Carla Schmidt, Christian Gerdes, Adam Nopora, Monika Patre, Samuel Moser, Peter Sondermann, Sylvia Herter, Barbara Guarino, Susanne Preiss, Valeria Nicoloni, Luise Wheat, Martin J. S. Dyer, Sibbrand Poppema, Sabine Bauer, Pamela Strein, Georg Fertig, Thomas Friess, Christian Klein.
- 11:25 4187 Radiation-guided anti-P-selectin antibody for tumor targeted imaging and therapy.** Ghazal Hariri, Ying Zhang, Zhaozhong Han, Martin Brechbiel, Todd Peterson, Ronald Baldwin, Dennis Hallahan.
- 11:40 4188 Immunoglobulin G fragment C receptor polymorphisms and response to trastuzumab-based treatment in patients with HER-2/ neu-positive metastatic breast cancer.** Antonino Musolino, Nadia Naldi, Beatrice Bortesi, Marzia Capelletti, Debora Pezzuolo, Maria Michiara, Gabriele Missale, Diletta Laccabue, Alessandro Zerbini, Roberta Camisa, Andrea Ardizzoni.
- 11:55 4189 CT-322: A specific VEGFR-2-blocking protein therapeutic agent with activity in pre-clinical tumor models comparable to pan-specific tyrosine kinase receptor inhibitors sunitinib and sorafenib.** Irvith M. Carvajal, Sarah Short, Yongchun Zhou, Janette Knowlton, Jennifer Jobin, Brent A. Morse, Roni Mamluk, Henry L. Wong, John D. Mendlein, Eric Furfine.
- 12:10 4190 Vasopermeation enhancement agents: A case study in screening for the most potent variant in a new class of compounds by using a novel avian embryonic system.** Kelly A. Felton, John D. Lewis, Andries Zijlstra, Jennifer Chase, Keith A. Luhrs, Aparna I. Roy, Debra A. Harris, Christian Frosch, Steven W. King, Missag H. Parseghian.
- 12:25 4191 A toll-like receptor 4 agonist enhances the efficacy of antibody therapy.** Igor A. Astsaturov, Shangzi Wang, Cathrine Bingham, Kenneth McCarthy, Yong Tang, Louis Weiner.
- 12:40 4192 Anti-HGF monoclonal antibody therapy inhibits lung tumorigenesis in transgenic mice overexpressing HGF.** Laura P. Stabile, Mary E. Rothstein, Stephanie R. Land, The Minh Luong, Jill M. Siegfried.
- 12:55 4193 Selective alpha-particle mediated depletion of tumor vasculature with vascular normalization.** Jaspreet S. Jaggi, Erik Henke, Surya Seshan, Barry Kappel, Debjit Chattopadhyay, Chad May, Michael R. McDevitt, Robert Benezra, David A. Scheinberg.
- 1:10 Discussion.**